Akebia Therapeutics (AKBA) Projected to Release Earnings on Thursday

Akebia Therapeutics (NASDAQ:AKBA) will likely be issuing its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Akebia Therapeutics to post earnings of ($0.03) per share and revenue of $48.8520 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 4:30 PM ET.

Akebia Therapeutics (NASDAQ:AKBA) last announced its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.03) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.02). Akebia Therapeutics had a negative return on equity of 62.72% and a negative net margin of 8.83%.The business had revenue of $53.54 million for the quarter, compared to analysts’ expectations of $51.67 million. On average, analysts expect Akebia Therapeutics to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Akebia Therapeutics Stock Down 0.8%

Shares of NASDAQ AKBA opened at $1.26 on Thursday. The stock has a fifty day moving average price of $1.14 and a 200 day moving average price of $1.27. The company has a current ratio of 1.40, a quick ratio of 1.33 and a debt-to-equity ratio of 1.33. Akebia Therapeutics has a 12-month low of $0.82 and a 12-month high of $3.81. The company has a market cap of $338.01 million, a P/E ratio of -15.75 and a beta of 0.23.

Insider Activity

In related news, CFO Erik Ostrowski sold 56,019 shares of the business’s stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $1.11, for a total value of $62,181.09. Following the transaction, the chief financial officer owned 616,616 shares in the company, valued at approximately $684,443.76. The trade was a 8.33% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 4.30% of the company’s stock.

Institutional Investors Weigh In On Akebia Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of AKBA. Vanguard Group Inc. raised its position in shares of Akebia Therapeutics by 6.4% in the 3rd quarter. Vanguard Group Inc. now owns 15,547,508 shares of the biopharmaceutical company’s stock valued at $42,445,000 after purchasing an additional 936,042 shares in the last quarter. State Street Corp grew its position in shares of Akebia Therapeutics by 15.6% during the fourth quarter. State Street Corp now owns 13,687,561 shares of the biopharmaceutical company’s stock worth $22,037,000 after buying an additional 1,842,792 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Akebia Therapeutics by 1.5% during the fourth quarter. Geode Capital Management LLC now owns 6,277,177 shares of the biopharmaceutical company’s stock worth $10,108,000 after buying an additional 92,226 shares in the last quarter. Goldman Sachs Group Inc. grew its position in shares of Akebia Therapeutics by 166.2% during the fourth quarter. Goldman Sachs Group Inc. now owns 4,706,437 shares of the biopharmaceutical company’s stock worth $7,577,000 after buying an additional 2,938,624 shares in the last quarter. Finally, UBS Group AG increased its stake in shares of Akebia Therapeutics by 470.2% in the third quarter. UBS Group AG now owns 3,646,233 shares of the biopharmaceutical company’s stock worth $9,954,000 after buying an additional 3,006,771 shares during the last quarter. 33.92% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Akebia Therapeutics in a research report on Wednesday, May 6th. Wall Street Zen downgraded Akebia Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. BTIG Research reissued a “buy” rating and set a $4.00 price target on shares of Akebia Therapeutics in a research report on Tuesday, April 7th. HC Wainwright restated a “buy” rating and issued a $6.00 price target on shares of Akebia Therapeutics in a report on Wednesday, July 1st. Finally, Zacks Research raised shares of Akebia Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 7th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $4.67.

About Akebia Therapeutics

Akebia Therapeutics, Inc, a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, is focused on the development and commercialization of therapies for patients with kidney disease. The company’s lead product candidate, vadadustat, is an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor designed to treat anemia associated with chronic kidney disease in both dialysis-dependent and non-dialysis patients. Akebia’s research and development efforts also extend to preclinical programs targeting nephrology and related metabolic disorders.

Since its founding in 2007, Akebia has pursued strategic collaborations to advance its clinical pipeline and expand its market reach.